- Siemens Healthineers will invest more than $32M in the company's laboratory diagnostics manufacturing facility located in Newark, DE.
- The project is expected to take 24 months.
- The goal of the project is to expand the company's manufacturing capabilities at the facility to accommodate growth in its manufacturing operations for the Atellica® Solution.
Siemens
Healthineers announced today it will invest more than $32 million in its
Glasgow Laboratory Diagnostics Manufacturing Facility located in Newark, Delaware.
The investment extends over 24 months and will enable the company to position
in Delaware manufacturing capabilities for more than 20 diagnostic tests. This
project is part of an initiative to drive greater efficiency, productivity, and
stability across the company's diagnostics supply chain.
“The Glasgow manufacturing facility expansion will further increase our manufacturing footprint in the United States—the largest healthcare market in the world,” said Deepak Nath, PhD, President of Laboratory Diagnostics, Siemens Healthineers. “As part of the expansion, we will relocate important test manufacturing to this facility, which will streamline some of our processes and further improve the efficiency with which we can deliver these important tests to healthcare providers and their patients.”
The Newark, DE facility employs more than 1,300
employees and manufactures more than 120 assays that run on certain instrument
platforms, including the Atellica® Solution, ADVIA® Chemistry, Dimension®,
Dimension Vista®, Syva Drug Testing, and Stratus® CS instruments—providing tests that help
physicians diagnose, monitor, and/or treat diseases.
The Glasgow manufacturing facility is one of several manufacturing
facilities Siemens Healthineers operates for its diagnostics portfolio.
Contact for journalists
Lance Longwell, Siemens Healthineers
Phone: 610-883-0788; Email: Lance.Longwell@siemens-healthineers.com
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the
future of healthcare. As a leading medical technology company headquartered in
Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide
through its regional companies to increase value by empowering them on their
journey towards expanding precision medicine, transforming care delivery,
improving the patient experience, and digitalizing healthcare. Siemens
Healthineers is continuously developing its product and service portfolio, with
AI-supported applications and digital offerings that play an increasingly
important role in the next generation of medical technology. These new
applications will enhance the company’s foundation in in-vitro diagnostics,
image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens
Healthineers also provides a range of services and solutions to enhance
healthcare providers’ ability to provide high-quality, efficient care to
patients. In fiscal 2020, which ended on September 30, 2020, Siemens
Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2
billion. Following the acquisition of Varian Medical Systems, Inc. the company
has approximately 66,000 employees worldwide. Further information is available
at www.siemens-healthineers.com.
